Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Results 1 - 20 of 146 : 1 2 3 4 5 6 7 8 Next »

Recs

0
Member Avatar TrackMagicFormul (85.88) Submitted: 6/11/2014 5:57:34 PM : Outperform Start Price: $33.08 MYGN Score: +8.83

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Jan 15 $31.00 strike at $4.10 has 20% discount and 21% annualized return.

Recs

0
Member Avatar jpat34721 (25.14) Submitted: 5/6/2014 9:44:48 PM : Outperform Start Price: $39.02 MYGN Score: -10.62

Great company in a high growth sector ( diagnostics )

Recs

0
Member Avatar MikeRosolanka (< 20) Submitted: 5/1/2014 4:34:56 PM : Outperform Start Price: $40.18 MYGN Score: -13.57

Profitable Biotech. Short squeeze about to ensue.

Recs

0
Member Avatar yooperking (67.99) Submitted: 4/28/2014 5:20:46 PM : Outperform Start Price: $39.40 MYGN Score: -11.50

Key Statistics (from Yahoo):
PEG Ratio (5 yr expected)1.16
Price/Sales (ttm): 3.84
Price/Book (mrq): 4.25
Profit Margin (ttm): 25.48%
Operating Margin (ttm): 39.51%
Return on Assets (ttm): 24.69%
Return on Equity (ttm): 28.07%
Qtrly Revenue Growth (yoy): 36.80%
Qtrly Earnings Growth (yoy): 43.70%
Total Cash Per Share (mrq): 4.85
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 6.74

Recs

0
Member Avatar csqrd (36.66) Submitted: 4/28/2014 2:22:19 PM : Outperform Start Price: $38.79 MYGN Score: -10.90

Very impressive sales growth, return on assets, and zero debt. The provision in the Health Care Act that does not allow discrimination based on pre-existing conditions is really going to support diagnostic companies like this. The fear of having the results used against participants appears to have been eliminated.

Recs

0
Member Avatar SpartanMAC (20.31) Submitted: 4/14/2014 10:07:10 PM : Outperform Start Price: $38.12 MYGN Score: -10.74

Top 30 @ $50M.

Recs

0
Member Avatar OKwarrior (25.98) Submitted: 3/25/2014 6:14:06 PM : Outperform Start Price: $35.39 MYGN Score: -1.11

biotech w/ profits!! This company has minimal debt & phenomenal ROIC and ROE. They are currently on a pullback, but it is time to jump in!

Recs

0
Member Avatar EdFromOhio (< 20) Submitted: 2/26/2014 4:16:38 PM : Underperform Start Price: $37.21 MYGN Score: +7.62

Too high, too fast.

Recs

0
Member Avatar collinriley2 (< 20) Submitted: 2/26/2014 2:54:24 PM : Outperform Start Price: $37.53 MYGN Score: -8.36

I have some shares.

Recs

0
Member Avatar neezeeann (< 20) Submitted: 2/10/2014 2:44:52 AM : Outperform Start Price: $32.14 MYGN Score: +5.16

I just have a feeling. This is going to 60 a share in 3 years. Amazing product line until the patents run out and then business will become competitive. Revs increasing setting up for the perfect storm on performance

Recs

0
Member Avatar modestus1 (< 20) Submitted: 2/5/2014 3:10:25 PM : Outperform Start Price: $31.98 MYGN Score: +2.94

Bought rival. Beat estimates.

Recs

1
Member Avatar mario1234 (< 20) Submitted: 1/18/2014 5:43:49 AM : Outperform Start Price: $24.86 MYGN Score: +41.85

Sold fundamentals. Why do doctors want to know your family history? To provide preventive guidance. The diagnostic tests this company provides quantify this information in a very specific way. Even though Medicare will no longer pay for these tests it in the younger patients not the elderly that are the target market. Affordable Care Act. In time the insurance companies will embrace this concept if it proves to cut cost of healthcare. The market over reacted to the court ruling. 47% of float shorted. Huge short squeeze on any good news.

Recs

0
Member Avatar oncqueen (67.51) Submitted: 12/31/2013 10:09:27 AM : Outperform Start Price: $20.76 MYGN Score: +70.97

I think the huge dip is an overreaction. I order 5 of these a month in my practice, and while there are others coming up with similar tests, there will be a lag time.

Recs

0
Member Avatar dillbeans (42.36) Submitted: 12/22/2013 10:55:44 PM : Outperform Start Price: $24.16 MYGN Score: +44.84

Greenblatt screen

Recs

1
Member Avatar healthcarevalue (97.47) Submitted: 10/30/2013 11:13:03 PM : Outperform Start Price: $24.74 MYGN Score: +37.39

Myriad Genetics, Inc. MYGN. Molecular diagnostic company. Interesting relatively newer niche field. Return on Invested Capital (ROIC) of 21.57 twelve-trailing-months is quite attractive. No debt/equity going back to 2004 indicates strong financial health. Trailing price/earnings ratio of 14.0 is lowest historical P/E going back 5 years to 2008. Market cap of 1.99 Billion leaves room to grow and/or be acquired. Currently priced 24.77, trading at lower end of 52 week range of 22.20 - 38.27.

Recs

1
Member Avatar dreamjob (91.96) Submitted: 10/2/2013 6:16:12 AM : Outperform Start Price: $25.37 MYGN Score: +28.47

Free cash flow / and Owner Earnings are growing. Double digit management returns (ROIC/CROIC). Manageable debt. Growing sales and earnings over the past few years. Operating cash flow out-pacing NI, and priced below intrinsic value to boot.

Recs

1
Member Avatar DrLinks (52.46) Submitted: 7/20/2013 11:26:09 PM : Outperform Start Price: $31.25 MYGN Score: +1.75

Massive Diagnostics Rx Cmpany!

Recs

0
Member Avatar VEGFR2 (< 20) Submitted: 6/19/2013 3:26:54 PM : Underperform Start Price: $25.95 MYGN Score: -22.44

BRCA1/2 testing competition from other companies that will utilize next gen sequencing techniques. Supreme court ruling eliminates Myriad's monopoly

Recs

0
Member Avatar jesterisdead (< 20) Submitted: 6/14/2013 2:11:51 AM : Underperform Start Price: $29.22 MYGN Score: -6.26

Lost BRCA1/BRCA2 patents. They are going down.

Recs

0
Member Avatar topsav1 (< 20) Submitted: 5/18/2013 5:27:15 PM : Outperform Start Price: $32.87 MYGN Score: -5.93

obama's buddies

Featured Broker Partners


Advertisement